StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly humalog (insulin lispro) — Worldwide revenue ($M) [legacy separate disclosure] ($M)

Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization)

QuarterlyAnnual
Latest, FY2024
2,325
Period ended Dec 31, 2024
Change on a year earlier
+39.8%
1,663 in FY2023
History
9 years
Since FY2016
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedHumalog (insulin lispro) — Worldwide revenue ($M) [legacy separate disclosure] ($M)Year on yearSource
FY2024Dec 31, 20242,325+39.8%Form 10-K FY2024 (filed 2025-02-19) ↗
FY2023Dec 31, 20231,663-19.3%Form 10-K FY2023 (filed 2024-02-21) ↗
FY2022Dec 31, 20222,061-16.0%Form 10-K FY2022 (filed 2023-02-22) ↗
FY2021Dec 31, 20212,453-6.6%Form 10-K FY2021 (filed 2022-02-23) ↗
FY2020Dec 31, 20202,626-12.4%Form 10-K FY2020 (filed 2021-02-17) ↗
FY2019Dec 31, 20192,997+4.6%Form 10-K FY2019 (filed 2020-02-19) ↗
FY2018Dec 31, 20182,8650.0%Form 10-K FY2018 (filed 2019-02-19) ↗
FY2017Dec 31, 20172,865+3.5%Form 10-K (filed 2018-02-20) ↗
FY2016Dec 31, 20162,769–Form 10-K (filed 2018-02-20) ↗

Breakdown

What makes up humalog (insulin lispro) — worldwide revenue ($m) [legacy separate disclosure]

Cite this data

StockData. (2026). Eli Lilly Humalog (insulin lispro) — Worldwide revenue ($M) [legacy separate disclosure] ($M), annual FY2016–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_humalog_ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.